pilot study of sbrt and cdx-1127 in prostate cancer

Conditions: Prostatic Neoplasms; Prostate Cancer

Summary: this study evaluates the combination of stereotactic body radiation therapy (sbrt) and cdx-1127 in subjects with castration resistant prostate cancer. subjects will be randomized to one of three arms to receive sbrt prior to, after, or in conjunction with the first dose of cdx-1127.

this pilot study will be conducted in subjects with metastatic prostate cancer in order to define whether inclusion of immune regulation agents such as cdx-1127 augments immune responses to sbrt-treated primary tumors or metastases, and whether inclusion of cdx-1127 in the treatment regimen results in immune responses in untreated metastases.

Eligibility criteria:
main inclusion criteria males, age ≥ 18 years. participants must have histologically-proven prostrate adenocarcinoma that is castrate-resistant. progressive disease is defined by one or more of the following: * a rise in psa on two successive determinations at least one week apart and psa level ≥2ng/ml. * soft-tissue progression defined by recist 1.1. * bone disease progression defined by pcwg2 with two or more new lesions on bone scan. patients must have castrate levels of testosterone (\<50 ng/dl \[1.74 nmol/l\]). patients must have undergone orchiectomy, or have been on lhrh agonists or antagonists, for at least 3 months prior to drug initiation. patients on lhrh agonists/antagonists must remain on these agents for the duration of the study. clinical metastases must be present and confirmed on imaging studies. participants for whom radiation therapy is recommended for the prostate gland (or prostate bed nodule) and/or bone or soft tissue metastases. sbrt may be administered to 1-4 sites and the treatment sites can include prostate gland (or prostate bed nodule for post-prostatectomy patients), bone metastases, and soft tissue metastases. participants must have at least one site of disease that will be both irradiated with sbrt and biopsied to evaluate immunological outcomes. ecog performance status 0-2. adequate hepatic and renal function. main exclusion criteria prior malignancies, that will affect the completion and interpretation of the study. patients with active cns metastases from prostate cancer. patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or other experimental therapy, or who have received this therapy within the preceding 4 weeks. patients who are currently receiving nitrosoureas or who have received this therapy within the preceding 6 weeks are excluded. patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or other experimental therapy, or who have received this therapy within the preceding 4 weeks. major surgery within 4 weeks prior to the start of study treatment. patients who are receiving or have previously been treated cdx-1127. hiv positivity evidence of active hepatitis b virus or hepatitis c virus. patients receiving the following medications at study entry or within the preceding 4 weeks (or longer, if otherwise specified) are excluded: 1. checkpoint inhibitors (within the preceding12 weeks) 2. allergy desensitization injections 3. systemic corticosteroids of more than 10 mg per day of prednisone (or equivalent), administered parenterally or orally, except for physiologic replacement. inhaled steroids (e.g. advair®, flovent®, azmacort®) are not permitted. topical corticosteroids are acceptable, including steroids with very low solubility administered nasally for local effects only (e.g. nasonex®) 4. any growth factors (e.g. gm-csf, g-csf, erythropoietin). 5. interferon or interleukin therapy 6. other agents with putative immunomodulating activity. (e.g. sipuleucel-t (provenge ®)) other investigational drugs or investigational therapy if the patient is currently taking those drugs/therapy, or if they have received the drugs/therapy within 4 weeks prior to the start of study treatment. participants must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement. significant cardiovascular disease. active bleeding disorders or evidence of chronic or acute disseminated intravascular coagulation (dic). concomitant therapeutic anticoagulation (i.e., warfarin) for reasons other than venous catheter patency.